TABLE 3.

Effect of preexisting immunity to Adhu5 on vaccine efficacya

Vaccine (dose [PFU])VNA titer (IU) (% survival upon challenge) with preexposure
NoneAdhu5
Adhu5rab.gp (2 × 107)972 (100)486 (100)
Adhu5rab.gp (2 × 106)486 (100)54 (100)
Adhu5rab.gp (2 × 105)486 (100)18 (40)
AdC68rab.gp (2 × 107)729 (100)729 (100)
AdC68rab.gp (2 × 106)486 (100)486 (100)
AdC68rab.gp (2 × 105)54 (100)54 (100)
None<0.5 (0)
  • a Groups of five C3H/He mice were injected with 4 × 108 PFU of an E1-deletion-containing Adhu5 virus expressing the L1 protein of HPV-16. Mice were injected 3 weeks later with various doses of Adhu5rab.gp or AdC68rab.gp. Sera were harvested 2 weeks later and tested for VNAs to rabies virus. Mice were then challenged with 10 LD50 of CVS-11 virus, and survival was recorded.